MUC1 and glioblastoma: NCT02839954 is a phase 1/2 trial investigating the safety and efficacy of anti-MUC1 CAR-NK cells in patients with relapsed or refractory solid tumors, including GBM, HCC, breast, pancreatic, gastric, and colorectal cancer expressing MUC1 [40].